|Day's Range||222.72 - 223.65|
|52 Week Range||182.27 - 225.77|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.04%|
In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).
The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vanguard S&P 500 ETF, Vanguard Mega Cap ETF, Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF and iShares Morningstar Large-Cap ETF
Don't fret over a declines in the Citigroup U.S. Economic Surprise Index. Expectations for economic growth have wavered but the economy and the stock market are not the same thing.